Page 340 - 2014 Printable Abstract Book
P. 340
project title is: “Strengthening of ‘Biological dosimetry’ in IAEA Member States: Improvement of current
techniques and intensification of collaboration and networking among the different institutes”. The major
aim is to increase the preparedness of biological dosimetry laboratories in IAEA Member States to react
on radiation and nuclear accidents nationally and regionally. The IAEA Project Officer is Mr Oleg Belyakov
and the Alternate Mr Eduardo Rosenblatt; it was initiated by Mr Jan Wondergem. The CRP is consisted of
25 participants among which are 20 research contract and 5 research agreement holders. The project is
funded by IAEA and Peaceful Uses Initiative. All participating institution work towards to the main goal of
strengthening biodosimetry in IAEA Member States. It includes but not limited to improvement of current
techniques, intensification of collaboration and networking among relevant organizations. These studies
include production of an in vitro dose - response curve for four main methods of cytogenetic
biodosimetry. During 2012-2013 CRP participants made a significant progress in establishing four major
methods of contemporary biodosimetry in their labs: conventional unstable chromosome analysis;
measurement of stable chromosome aberrations with FISH - fluorescent in situ method; premature
chromosome condensation analysis and the cytokinesis-block micronucleus assay. The ultimate goal of
the project is to create an international research biodosimetric network. In order to achieve this aim
periodic Research Coordination Meetings (RCM) are arranged. The next, second RCM will take place on
10-13 June 2014 at IAEA headquarters, Vienna, Austria. Apart from that, trainings carried out such as
“Biodosimetry in the 21st century” in Hiroshima, Japan on 10-14 June 2013. This meeting was arranged
by the Hiroshima International Council for Health Care of the Radiation-Exposed in collaboration with the
IAEA. At the end of the project we plan to organize an Exploratory Workshop on the “Future of
Biodosimetry” in collaboration with National Institute of Radiological Science, Japan in 2015.
(PS6-26) Targeted and Discovery-based Mass Spectrometry Metabolomics for Biomarker Identification
1
1
and Validation in Mouse and Non-Human Primate Radiation Models. Jace W. Jones, PhD ; Fei Li, PhD ;
3
3
2
1
1
1
Claire L. Carter, PhD ; Grerory Tudor ; Alexander Bennett ; Ann M. Farese ; Yan Tong ; Barry Katz, PhD ;
2
1
1
Catherine Booth, PhD ; Thomas J. MacVittie, PhD ; and Maureen A. Kane, PhD
1
2
University of Maryland, Baltimore, MD ; Epistem Ltd, Manchester, United Kingdom ; and Indiana
3
University, Indianapolis, IN
Identification of biomarkers that accurately model radiation-induced damage is critically
important. An ideal biomarker has the potential to provide early indication of a radiation-induced
syndrome prior to the onset of organ-specific damage. Additionally, validated biomarkers provide
mechanistic details for understanding radiation-induced tissue damage. To this effect, we utilized a liquid
chromatography tandem mass spectrometry platform to perform targeted and un-targeted metabolomic
studies to identify and validate unique plasma and tissue biomarkers for radiation-induced injuries.
Metabolite biomarkers are of great interest in that they are readily detected in accessible physiological
fluids (e.g., blood) and tissue. Furthermore, metabolites represent the end product of cellular processes
resulting from genetic and environmental influences. Thus, metabolite biomarkers have the potential to
link cellular dysfunction to phenotype. Plasma and gastrointestinal (GI) tissue samples were procured
from mouse and non-human primates that were exposed to total-body irradiation (TBI) or partial-body
irradiation (PBI) at doses that result in acute and delayed GI and hematopoietic injuries. Our preliminary
data indicates differential abundance of unique amino acids, biogenic amines, and lipids between control
and irradiated samples. On-going efforts are being investigated to link circulating biomarkers to tissue
specific biomarkers that are dose- and time-dependent following radiation exposure. In addition,
338 | P a g e
techniques and intensification of collaboration and networking among the different institutes”. The major
aim is to increase the preparedness of biological dosimetry laboratories in IAEA Member States to react
on radiation and nuclear accidents nationally and regionally. The IAEA Project Officer is Mr Oleg Belyakov
and the Alternate Mr Eduardo Rosenblatt; it was initiated by Mr Jan Wondergem. The CRP is consisted of
25 participants among which are 20 research contract and 5 research agreement holders. The project is
funded by IAEA and Peaceful Uses Initiative. All participating institution work towards to the main goal of
strengthening biodosimetry in IAEA Member States. It includes but not limited to improvement of current
techniques, intensification of collaboration and networking among relevant organizations. These studies
include production of an in vitro dose - response curve for four main methods of cytogenetic
biodosimetry. During 2012-2013 CRP participants made a significant progress in establishing four major
methods of contemporary biodosimetry in their labs: conventional unstable chromosome analysis;
measurement of stable chromosome aberrations with FISH - fluorescent in situ method; premature
chromosome condensation analysis and the cytokinesis-block micronucleus assay. The ultimate goal of
the project is to create an international research biodosimetric network. In order to achieve this aim
periodic Research Coordination Meetings (RCM) are arranged. The next, second RCM will take place on
10-13 June 2014 at IAEA headquarters, Vienna, Austria. Apart from that, trainings carried out such as
“Biodosimetry in the 21st century” in Hiroshima, Japan on 10-14 June 2013. This meeting was arranged
by the Hiroshima International Council for Health Care of the Radiation-Exposed in collaboration with the
IAEA. At the end of the project we plan to organize an Exploratory Workshop on the “Future of
Biodosimetry” in collaboration with National Institute of Radiological Science, Japan in 2015.
(PS6-26) Targeted and Discovery-based Mass Spectrometry Metabolomics for Biomarker Identification
1
1
and Validation in Mouse and Non-Human Primate Radiation Models. Jace W. Jones, PhD ; Fei Li, PhD ;
3
3
2
1
1
1
Claire L. Carter, PhD ; Grerory Tudor ; Alexander Bennett ; Ann M. Farese ; Yan Tong ; Barry Katz, PhD ;
2
1
1
Catherine Booth, PhD ; Thomas J. MacVittie, PhD ; and Maureen A. Kane, PhD
1
2
University of Maryland, Baltimore, MD ; Epistem Ltd, Manchester, United Kingdom ; and Indiana
3
University, Indianapolis, IN
Identification of biomarkers that accurately model radiation-induced damage is critically
important. An ideal biomarker has the potential to provide early indication of a radiation-induced
syndrome prior to the onset of organ-specific damage. Additionally, validated biomarkers provide
mechanistic details for understanding radiation-induced tissue damage. To this effect, we utilized a liquid
chromatography tandem mass spectrometry platform to perform targeted and un-targeted metabolomic
studies to identify and validate unique plasma and tissue biomarkers for radiation-induced injuries.
Metabolite biomarkers are of great interest in that they are readily detected in accessible physiological
fluids (e.g., blood) and tissue. Furthermore, metabolites represent the end product of cellular processes
resulting from genetic and environmental influences. Thus, metabolite biomarkers have the potential to
link cellular dysfunction to phenotype. Plasma and gastrointestinal (GI) tissue samples were procured
from mouse and non-human primates that were exposed to total-body irradiation (TBI) or partial-body
irradiation (PBI) at doses that result in acute and delayed GI and hematopoietic injuries. Our preliminary
data indicates differential abundance of unique amino acids, biogenic amines, and lipids between control
and irradiated samples. On-going efforts are being investigated to link circulating biomarkers to tissue
specific biomarkers that are dose- and time-dependent following radiation exposure. In addition,
338 | P a g e
